**5.3 Midostaurin in** *FLT3***-mutated AML**

Midostaurin was approved on 28 April 2017 by FDA for patients with AML who had FLT3 mutations. Midostaurin is an oral small molecule FLT3 inhibitor that inhibits wild-type and mutant FLT3 kinases as well as a number of other factors. The recommended dose of midostaurin is 50 mg capsules given twice daily on days 8–21, with cytarabine (200 mg/m2 ), continuously for 7 days (d1–7) and 60 mg/m2 daunorubicin for 3 days on (d1–3) and also repeat same dose of midostaurin daily for 2 weeks (day 8–21) in each cycle of consolidation in combination with high dose of cytarabine [29].
